US 20150284727A1
· Kim et al.
· 2015
[cited by applicant]
US 20160237455A1
· Glucksmann et al.
· 2016
[cited by applicant]
CN 105164264A
· 2015
[cited by applicant]
KR 1020160044457A
· 2016
[cited by applicant]
KR 1020160102056A
· 2016
[cited by applicant]
KR 101656237B1
· 2016
[cited by applicant]
WO WO2008154644A1
· 2008
[cited by applicant]
WO WO2015048577A2
· 2015
[cited by applicant]
WO WO2015188056A1
· 2015
[cited by applicant]
WO WO2016021973A1
· 2016
[cited by applicant]
WO WO2017070633A2
· 2017
[cited by applicant]
Miller, Jeffrey, 2015, US 20150353917 A1.
[cited by examiner]
Zhang et al., 2014, Geneseq Accession No. BBS43273, computer printout, pp. 1-3.
[cited by examiner]
Saberan-Djoneidi et al., 2000, GenEmbl Accession No. AF059314, computer printout, p. 1-2.
[cited by examiner]
Joung et al., 2014, Geneseq Accession No. BBN11743, computer printout, pp. 1-2.
[cited by examiner]
Charpentier et al., 2013, Geneseq Accession No. BAZ50216, computer printout, pp. 1-2.
[cited by examiner]
Sutter et al., 1995, GenEmbl Accession No. U08049, computer printout, pp. 1-2.
[cited by examiner]
Doench, et al: “Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.”,
[cited by applicant]
Pantera, et al: “A Genome Editing Approach to Studying Pmp22 Enhancer Functionality.”,
[cited by applicant]
Lee, et al: “Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.”,
[cited by applicant]
Van Paassen, et al: “PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.”,
[cited by applicant]
Arnold, et al: “The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management.”,
[cited by applicant]
Partial Supplementary European Search Report, dated May 26, 2020, issued for corresponding European Patent Application No. EP 17869218.2.
[cited by applicant]
Liu, et al: “Knockdown of Peripheral Myelin Protein 22 Inhibits the Progression of Chronic Myeloid Leukemia.”
[cited by applicant]
Doench, et al: “Supplementary information to Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9—Table 21, excerpt”, XP55683076.
[cited by applicant]
Doench, et al: “Supplementary information to Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9—Table 22, excerpt”, XP55683080.
[cited by applicant]
Morales, et al: “Rewiring Integrin-Mediated Signaling and Cellular Response with the Peripheral Myelin Protein 22 and Epithelial Membrane Protein 2 Components of the Tetraspan Web”,
[cited by applicant]
Li, J., et al.; “
[cited by applicant]
Hai, M., et al.; “Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene”, Journal of Neuroscience Research 65:508-519 (2001).
[cited by applicant]
International Search Report from corresponding PCT Application No. PCT/KR2017/010897, dated Jan. 29, 2018.
[cited by applicant]
Written Opinion of the International Searching Authority from corresponding PCT Application No. PCT/KR2017/010897, dated Jan. 29, 2018.
[cited by applicant]
Search Report and Written Opinion from corresponding Singapore Patent Application No. 11201904241W, dated Jul. 2, 2020.
[cited by applicant]
Office Action from corresponding Korean Patent Application No. 10-2017-0126636, issued Jul. 20, 2020.
[cited by applicant]
Kim, H., et al.; “A simple, flexible and high-throughput cloning system for plant genome editing via CRISPR-Cas system”, Journal of Integrative Plant Biology, vol. 58, pp. 702-712, 2016.
[cited by applicant]
Office Action from corresponding Japanese Patent Application No. 2019-524226, issued Nov. 9, 2021.
[cited by applicant]
Office Action from corresponding Russian Patent Application No. 2019118283, issued Apr. 26, 2021.
[cited by applicant]
Avdeeva, Z.I et al., The safety of medicines of monoclonal antibodies connected with manifestation of their immunogenicity, Immunology, No. 4, 2015, p. 247-256 (see p. 248) [in Russian].
[cited by applicant]
Avdeeva, Z.I. et al., Requirements for production and control of medicines based on monoclonal antibodies used for treatment, Biopreparations, 2010, pp. 11-14 (see p. 13) [in Russian].
[cited by applicant]
Notice of Allowance from corresponding Russian Patent Application No. 2019118283, issued Dec. 7, 2021.
[cited by applicant]
Suter U., et al.; “Regulation of Tissue-specific Expression of Alternative Peripheral Myelin Protein-22 (P M. 2 2) Gene Transcripts by Two Promoters”, J. Biol. Chem., vol. 269, No. 41, Oct. 14, 1994 (Oct. 14, 1994), pp.…
[cited by applicant]
Extended European Search Report from corresponding European Patent Application No. 21166447.9, issued Sep. 22, 2021.
[cited by applicant]
Shijie Huaren Xiaohua Zashi, 2015, vol. 23, p. 3742-3748.
[cited by applicant]
Mehreen Hai et al: Competitive Binding of Triplex-Forming Oligonucleotides in the Two Alternate Promoters of the PMP22 Gene11?Antisense & Nucleic Acid Drug Development., vol. 11, No. 4, Aug. 2001 (Aug. 2001) pp. 233-246…
[cited by applicant]
Office Action from corresponding Japanese Patent Application No. 2019-524226, dated Jul. 5, 2022.
[cited by applicant]
Journal of Integrative Plant Biology, Aug. 2016, vol. 58, p. 705-712.
[cited by applicant]
Office Action from corresponding Chinese Patent Application No. 201780083263.5, dated Sep. 28, 2022.
[cited by applicant]